Clinical Trial Update: Long - Term Follow Up of Sickle Cell Disease and Beta-thalassemia Subjects Previously Exposed to BIVV003 or ST-400.

View source ↗

Summary

Sangamo Therapeutics provides an update on long-term follow-up for sickle cell disease and beta-thalassemia subjects previously treated with BIVV003 or ST-400; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Sickle Cell Disease

Drugs mentioned

• BIVV003
• ST-400

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Blood and Lymphatic Diseases | Status: ACTIVE_NOT_RECRUITING